What is Entyvio?

Entyvio (vedolizumab) is a first-in-class, gut-selective biologic treatment for moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.1,2

LEARN MORE

Licensed Indications

Entyvio is indicated for the treatment of adult patients with:1,2

  • Moderately to severely active ulcerative colitis (UC)
  • Moderately to severely active Crohn’s disease (CD)
Who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist

PRESCRIBING ENTYVIO

Ulcerative Colitis

Entyvio now offers both IV (intravenous) and SC (subcutaneous) options.1,2 Entyvio IV is given by intravenous infusion every 8 weeks after an initial induction phase.1 Entyvio SC is given by subcutaneous injection every 2 weeks after an initial induction phase with Entyvio IV.2 Treatment with Entyvio should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn’s disease.1,2

LEARN MORE

WHY PRESCRIBE ENTYVIO?

Ulcerative Colitis

The safety and efficacy of newly licensed Entyvio SC are supported by the results of the phase III VISIBLE studies.2,4,5 In VISIBLE I and VISIBLE II, Entyvio SC was an effective maintenance therapy with a favourable safety profile, providing long-term remission in patients with UC and CD.4,5 The safety and efficacy of Entyvio IV for UC and CD have been established in the pivotal GEMINI studies, the real-world EVOLVE study, and the head-to-head VARSITY study.6-11

LEARN MORE

ABOUT TAKEDA

Ulcerative Colitis

Takeda Pharmaceutical Company Limited has a long history in the research and development, manufacturing, sales and marketing, and import/export of pharmaceutical products. The corporate mission to “strive towards better health for people worldwide through leading innovation in medicine” has led to the development of many medicines, including Entyvio for UC and CD.

LEARN MORE

RESOURCES

Ulcerative Colitis

In the resources section you can find a range of support materials for healthcare professionals including videos featuring data insights from key opinion leaders, materials for you to download, and practice resources such as the Entyvio dosing algorithms. The resources section also hosts a range of materials to help you support your patients: you can download, Entyvio IV and Entyvio SC patient support booklets, watch Entyvio SC administration videos and the mode of action animation, and access other important patient resources such as the Patient Alert Card (PAC) and Patient Information Leaflet (PIL).

LEARN MORE

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Takeda by e-mail at DSO-UK@takeda.com